The FDA enforcement report lists a Class II recall of several compounded semaglutide sterile multi-dose vials from Apollo Care, LLC, in strengths from 0.9 mg/mL to 5 mg/mL, some combined with glycine. The reason given is particulate matter identified as nylon or polyamide and silk or protein-type material. The recall status is ongoing.
Class II means the product may cause temporary or medically reversible harm, or that serious harm is unlikely. It is a recall of specific compounded products from one US firm, not a safety finding about semaglutide itself or about branded pens.
The relevance beyond the US is the pattern. Compounded and non-branded semaglutide is widely sold online and through clinics, including to patients in India, and injectable particulate contamination is exactly the kind of defect a patient cannot see. The recall was posted on 19 August 2026.
- Ask patients on semaglutide where their supply comes from
- Branded, pharmacy-dispensed pens are not affected by this recall
- Injection-site reactions or abscesses in a patient using vials should prompt a question about the source
- Advise against multi-dose vials bought online without a traceable pharmacy
Why it matters
Patients rarely volunteer that their GLP-1 comes from a compounder or an online seller, and the product risk is invisible to them.
Don't overread it
This is a manufacturing defect in one firm's compounded vials, not a new safety signal for semaglutide.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free